Highlander Capital Management LLC decreased its stake in Zoetis Inc (NYSE:ZTS) by 17.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,675 shares of the company’s stock after selling 2,000 shares during the period. Highlander Capital Management LLC’s holdings in Zoetis were worth $785,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Kiwi Wealth Investments Limited Partnership raised its position in Zoetis by 95.4% in the first quarter. Kiwi Wealth Investments Limited Partnership now owns 42,567 shares of the company’s stock worth $3,555,000 after acquiring an additional 20,778 shares during the period. Verition Fund Management LLC raised its position in Zoetis by 422.7% in the first quarter. Verition Fund Management LLC now owns 18,860 shares of the company’s stock worth $1,575,000 after acquiring an additional 15,252 shares during the period. Hilltop Holdings Inc. bought a new stake in Zoetis in the first quarter worth about $231,000. Permanens Capital L.P. bought a new stake in Zoetis in the first quarter worth about $334,000. Finally, Amundi Pioneer Asset Management Inc. raised its position in Zoetis by 319.9% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 2,768,388 shares of the company’s stock worth $231,187,000 after acquiring an additional 2,109,036 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have commented on ZTS shares. Cowen set a $85.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research report on Thursday, February 15th. BMO Capital Markets set a $78.00 target price on shares of Zoetis and gave the stock a “hold” rating in a research note on Thursday, February 15th. Cantor Fitzgerald set a $90.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research note on Thursday, February 15th. Bank of America lifted their target price on shares of Zoetis from $80.00 to $87.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $86.00 target price (up previously from $84.00) on shares of Zoetis in a research note on Friday, February 16th. One analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $84.25.

In related news, insider Kristin C. Peck sold 4,877 shares of the business’s stock in a transaction that occurred on Tuesday, May 1st. The shares were sold at an average price of $83.46, for a total transaction of $407,034.42. Following the completion of the transaction, the insider now owns 42,652 shares of the company’s stock, valued at $3,559,735.92. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Heidi C. Chen sold 7,383 shares of the business’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $84.71, for a total transaction of $625,413.93. Following the transaction, the insider now directly owns 20,162 shares of the company’s stock, valued at approximately $1,707,923.02. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,277 shares of company stock valued at $1,033,899. 0.35% of the stock is owned by corporate insiders.

Zoetis traded up $0.14, hitting $87.50, during mid-day trading on Thursday, MarketBeat Ratings reports. 12,522 shares of the stock traded hands, compared to its average volume of 2,609,786. The stock has a market cap of $42.13 billion, a P/E ratio of 36.46, a P/E/G ratio of 1.92 and a beta of 0.98. Zoetis Inc has a 12-month low of $59.50 and a 12-month high of $88.16. The company has a current ratio of 4.27, a quick ratio of 2.83 and a debt-to-equity ratio of 2.51.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Wednesday, May 2nd. The company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.69 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.35 billion. Zoetis had a net margin of 17.97% and a return on equity of 68.51%. Zoetis’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.53 earnings per share. equities analysts forecast that Zoetis Inc will post 3.06 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 4th. Investors of record on Friday, July 20th will be paid a dividend of $0.126 per share. The ex-dividend date is Thursday, July 19th. This represents a $0.50 annualized dividend and a yield of 0.58%. Zoetis’s dividend payout ratio is currently 20.83%.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.